Sen-Jam Pharmaceutical Nears Completion of SJP-002C Trial, Promising Affordable Respiratory Treatment

HUNTINGTON, N.Y., May 22, 2024 -- Sen-Jam Pharmaceutical, a pioneer in therapeutic development for age-related diseases, has announced that it is close to completing its clinical trial for the innovative treatment SJP-002C, scheduled for July 2024. This new therapeutic aims to combat Upper Respiratory Infections (URIs), including COVID-19, offering a promising solution to global healthcare challenges with its safety, efficacy, and accessibility.

The COVID-19 pandemic has exposed the limitations of current treatments for URIs, which often involve high costs, significant side effects, and limited availability. Millions of patients lack sufficient care, highlighting an urgent need for innovative solutions. SJP-002C is designed to address these gaps in the market by providing an oral, anti-inflammatory treatment that reduces symptoms and minimizes hospitalizations, which can cost between $51,389 and $78,569 based on variables like age and insurance.

Jim Iversen, Co-Founder and CEO of Sen-Jam Pharmaceutical, expressed enthusiasm about the trial's progress, underscoring the need for effective oral anti-inflammatories in the market. The Phase 2 clinical trial for SJP-002C, conducted with the expertise of Dr. Ashley St. John and Dr. Alexander Limkakeng from Duke University, has shown promising results. Preliminary in vitro studies demonstrated a substantial reduction in viral load and symptom severity due to the synergistic effect of two anti-inflammatory agents.

With patents filed in 15 countries and a streamlined, patented manufacturing process developed with KVK Tech, SJP-002C is on track for swift global deployment following regulatory approval. Utilizing the 505(b)(2) pathway, Sen-Jam Pharmaceutical seeks to expedite the approval process, ensuring rapid availability of this crucial treatment. The company's collaboration with KVK-Tech has led to the completion of formulation, Chemistry, Manufacturing, and Controls (CMC) work, the production of GMP-compliant products, and the preparation of FDA submission batches.

The potential market for SJP-002C is vast, with the global respiratory infection market valued at $35 billion in 2023 and the COVID-19 therapeutics market alone worth $16 billion. SJP-002C's cost-effective and highly effective nature positions it to capture a significant portion of these markets, providing accessible care to patients worldwide.

Iversen emphasized SJP-002C's transformative potential in treating URIs and COVID-19, focusing on acute and chronic inflammation as root causes rather than consequences of these infections. He called for a more precise approach to managing inflammation, particularly neuroinflammation, to significantly improve health outcomes and save lives.

Renowned Immunologist Dr. Ashley St. John from Duke-National University of Singapore echoed this sentiment, advocating for advanced therapeutic methods to mitigate runaway inflammation, a common factor in many conditions. Dr. St. John has recently been honored with a prestigious National Research Foundation Award for her groundbreaking work in immunology.

Sen-Jam Pharmaceutical is actively seeking retail investors, investment partners, and strategic collaborations to support Phase 3 clinical trials and global licensing for SJP-002C's commercialization. Additionally, the company is progressing with ten other novel assets, three of which are nearing or at Phase 2 clinical trials. Sen-Jam's platform is set to revolutionize inflammation treatment and the pharmaceutical industry's approach to healthcare.

Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company, is dedicated to repurposing small molecules through the 505(b)(2) pathway to develop innovative therapeutics for age-related diseases. With a mission to address significant unmet medical needs, the company is committed to enhancing patient lives with safe, effective, and accessible treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!